KAMA FLOW together with the company Digital Medicine in the framework of the X Telemedforum gathered a base of companies and organisations forming an ecosystem of support for biomedtech projects.

The base was presented on 14 March at the M.M. Krasnov Research Institute of Information and Information Technologies at the round table ‘No Money, Startups Are. What is the secret?’, dedicated to the discussion of piloting and selling products at early stages, technology transfer, and current market trends.

The base identifies key players that form the ecosystem of support for biomedical projects at all stages of company growth - from support at the start, provided by research institutes and universities, startup centres and accelerators, to infrastructure support for technoparks and clusters, development institutions, as well as key investors systematically investing in biomedtech.

According to Sergey Gaivoronsky, Investment Director of KAMA FLOW, Russian biomedical technology projects remain consistently attractive to venture capitalists. However, in order to unlock their full potential, it is critical to strengthen coordination between private capital providers, regulators and key stakeholders in the industry.

‘It is no secret that the public sector prevails in the Russian healthcare market, so the key aspect of successful nurturing of technological leaders will be the development of a common understanding of the strategic development goals of the biomedical sector, clear mechanisms for their implementation, as well as the joint development and adjustment of the entire set of measures to support innovative projects. This will help to maintain a balance between risks and opportunities, and, most importantly, to remove uncertainty about the long-term development vectors of various market segments, which, in my opinion, is the main obstacle to further growth of investments in the industry’ - said Sergey.

The full version of the base can be found in our Telegram channel https://t.me/kamaflow/708.